Methotrexate trimethoprim — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Bone marrow suppression risk
This scenario assesses Methotrexate trimethoprim in a UK pharmacy practice context. Trimethoprim increases antifolate toxicity risk when combined with methotrexate. The best answer is Bone marrow suppression risk because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.
Reference: BNF